265 related articles for article (PubMed ID: 27756456)
21. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
[TBL] [Abstract][Full Text] [Related]
22. River blindness elimination in Columbia.
Burki T
Lancet Infect Dis; 2013 Nov; 13(11):922-3. PubMed ID: 24319775
[No Abstract] [Full Text] [Related]
23. Preliminary evaluations of 3-dimensional human skin models for their ability to facilitate in vitro the long-term development of the debilitating obligatory human parasite Onchocerca volvulus.
Malkmus C; Jawahar S; Tricoche N; Lustigman S; Hansmann J
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008503. PubMed ID: 33151944
[TBL] [Abstract][Full Text] [Related]
24. Population biology of human onchocerciasis.
Basáñez MG; Boussinesq M
Philos Trans R Soc Lond B Biol Sci; 1999 Apr; 354(1384):809-26. PubMed ID: 10365406
[TBL] [Abstract][Full Text] [Related]
25. Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes.
Lont YL; Coffeng LE; de Vlas SJ; Golden A; de Los Santos T; Domingo GJ; Stolk WA
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005314. PubMed ID: 28114304
[TBL] [Abstract][Full Text] [Related]
26. The need for evidence-based strategies and tools for onchocerciasis elimination in Africa.
Dadzie Y; Amazigo UV; Boatin BA; Sékétéli A
Infect Dis Poverty; 2019 Jul; 8(1):62. PubMed ID: 31303174
[TBL] [Abstract][Full Text] [Related]
27. The positive influence the Onchocerciasis Elimination Program for the Americas has had on Africa programs.
Richards FO; Nwoke BEB; Zarroug I; Tukahebwa E; Negussu N; Higazi TB; Oguttu D; Tadesse Z; Miri E; Aziz N; Habomugisha P; Katabarwa M
Infect Dis Poverty; 2019 Jul; 8(1):52. PubMed ID: 31303175
[TBL] [Abstract][Full Text] [Related]
28. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness.
Bhattacharyya S; Vinkeles Melchers NVS; Siewe Fodjo JN; Vutha A; Coffeng LE; Logora MY; Colebunders R; Stolk WA
PLoS Negl Trop Dis; 2023 May; 17(5):e0011320. PubMed ID: 37235598
[TBL] [Abstract][Full Text] [Related]
29. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.
Awadzi K; Opoku NO; Attah SK; Lazdins-Helds J; Kuesel AC
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2953. PubMed ID: 24968000
[TBL] [Abstract][Full Text] [Related]
30. Ten years of NGDO action against river blindness.
Drameh PS; Richards FO; Cross C; Etya'alé DE; Kassalow JS
Trends Parasitol; 2002 Sep; 18(9):378-80. PubMed ID: 12377246
[TBL] [Abstract][Full Text] [Related]
31. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
[TBL] [Abstract][Full Text] [Related]
32. From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes.
Colebunders R; Siewe Fodjo JN; Hopkins A; Hotterbeekx A; Lakwo TL; Kalinga A; Logora MY; Basáñez MG
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007407. PubMed ID: 31318857
[No Abstract] [Full Text] [Related]
33. Moxidectin: an oral treatment for human onchocerciasis.
Milton P; Hamley JID; Walker M; Basáñez MG
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787
[TBL] [Abstract][Full Text] [Related]
34. [The use of ivermectin in the control of onchocerciasis].
Chippaux JP; Boussinesq M; Prod'hon J
Sante; 1995; 5(3):149-58. PubMed ID: 7640897
[TBL] [Abstract][Full Text] [Related]
35. The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole.
Awadzi K; Addy ET; Opoku NO; Plenge-Bönig A; Büttner DW
Trop Med Parasitol; 1995 Dec; 46(4):213-20. PubMed ID: 8826100
[TBL] [Abstract][Full Text] [Related]
36. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward.
Ndyomugyenyi R; Lakwo T; Habomugisha P; Male B
Ann Trop Med Parasitol; 2007 Jun; 101(4):323-33. PubMed ID: 17524247
[TBL] [Abstract][Full Text] [Related]
37. Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis.
Jawahar S; Tricoche N; Bulman CA; Sakanari J; Lustigman S
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009064. PubMed ID: 33600426
[TBL] [Abstract][Full Text] [Related]
38. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results.
Tekle AH; Zouré HG; Noma M; Boussinesq M; Coffeng LE; Stolk WA; Remme JH
Infect Dis Poverty; 2016 Jun; 5(1):66. PubMed ID: 27349645
[TBL] [Abstract][Full Text] [Related]
39. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa.
Kim YE; Remme JH; Steinmann P; Stolk WA; Roungou JB; Tediosi F
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003664. PubMed ID: 25860569
[TBL] [Abstract][Full Text] [Related]
40. Can ivermectin mass treatments eliminate onchocerciasis in Africa?
Winnen M; Plaisier AP; Alley ES; Nagelkerke NJ; van Oortmarssen G; Boatin BA; Habbema JD
Bull World Health Organ; 2002; 80(5):384-91. PubMed ID: 12077614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
